{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:32:17Z","timestamp":1792276337285,"version":"4.4.0"},"reference-count":96,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:sec><jats:title>Purpose of review<\/jats:title><jats:p>Despite recent developments and treatment successes, the outcome, and prognosis of patients with lupus nephritis (LuN) have not greatly changed since the 1980s. This review covers the application of new concepts to the understanding of renal inflammation and the study of new pharmacologic agents to improve patient outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent findings<\/jats:title><jats:p>Studies have shown that the presence of anti-vimentin antibodies and T follicular helper cells in patient biopsies is associated with more severe interstitial inflammation, which has been tied to faster disease progression and onset of end-stage renal disease. Additionally, data regarding the role of serum IgE antidouble-stranded DNA antibodies in LuN by means of mediating IFN1 production by plasmacytoid dendritic cells are highlighted. Finally, a thorough review of completed and currently open clinical trials of therapeutic agents is provided.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Current management of LuN is guided almost exclusively by glomerular involvement. Based on the data provided in this review, we argue that renal tubulointerstitial inflammation is no less important and represents an overlooked feature in the current clinical approach to patients. Tubulointerstitial inflammation is driven by both adaptive and innate immune mechanisms that are still poorly understood. Studying these pathogenic processes promises to reveal new therapeutic opportunities for those LuN patients with the worst prognosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Video abstract<\/jats:title><jats:p>Alternate video abstract introduction (see Video, Supplemental Digital Content 1, with introduction by two of the authors \u2013 VL and KT). Abstract Video: http:\/\/links.lww.com\/COR\/A35<\/jats:p><\/jats:sec>","DOI":"10.1097\/bor.0000000000000319","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T14:39:51Z","timestamp":1466692791000},"page":"460-467","source":"Crossref","is-referenced-by-count":15,"title":["Overview of pathophysiology and treatment of human lupus nephritis"],"prefix":"10.1097","volume":"28","author":[{"given":"Kimberly","family":"Trotter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus R.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir M.","family":"Liarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.amjmed.2004.04.029","article-title":"Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus","volume":"117","author":"Mok","year":"2004","journal-title":"Am J Med"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000 patients","volume":"82","author":"Cervera","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.21955","article-title":"Mortality in systemic lupus erythematosus","volume":"54","author":"Bernatsky","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.1780370417","article-title":"Kidney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables","volume":"37","author":"McLaughlin","year":"1994","journal-title":"Arthritis Rheum"},{"key":"R5-20230828","first-page":"1892","article-title":"Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity","volume":"27","author":"Cook","year":"2000","journal-title":"J Rheumatol"},{"key":"R6-20230828","first-page":"CD0002922","article-title":"Treatment for lupus nephritis","author":"Flanc","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1681\/ASN.2006090992","article-title":"Severe lupus nephritis:racial differences in presentation and outcome","volume":"18","author":"Korbet","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/096120339500400206","article-title":"Prognostic determinants in lupus nephritis: a long-term clinicopathologic study","volume":"4","author":"Donadio","year":"1995","journal-title":"Lupus"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0049-0172(95)80017-4","article-title":"Lupus in the 1980\u200as: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center","volume":"25","author":"Neumann","year":"1995","journal-title":"Semin Arthritis Rheum"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"Austin","year":"1986","journal-title":"N Engl J Med"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1440-1797.2005.00444.x","article-title":"Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis","volume":"10","author":"Ong","year":"2005","journal-title":"Nephrology (Carlton)"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"15","author":"Weening","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group","volume":"343","author":"Chan","year":"2000","journal-title":"N Engl J Med"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.amjmed.2005.08.045","article-title":"Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide","volume":"119","author":"Mok","year":"2006","journal-title":"Am J Med"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrrheum.2015.174","article-title":"Towards new avenues in the management of lupus glomerulonephritis","volume":"12","author":"Mok","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"key":"R23-20230828","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","article-title":"Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","article-title":"Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis","volume":"75","author":"Tamirou","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1681\/ASN.2008060665","article-title":"Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy","volume":"20","author":"Austin","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ki.2009.412","article-title":"Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis","volume":"77","author":"Radhakrishnan","year":"2010","journal-title":"Kidney Int"},{"key":"R27-20230828","first-page":"175","article-title":"Lupus membranous nephropathy: long-term outcome","volume":"39","author":"Pasquali","year":"1993","journal-title":"Clin Nephrol"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1191\/096120399678847605","article-title":"Clinical characteristics and outcome of southern Chinese males with systemic lupus erythematosus","volume":"8","author":"Mok","year":"1999","journal-title":"Lupus"},{"key":"R29-20230828","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.rdc.2014.05.001","article-title":"Recent clinical trials in lupus nephritis","volume":"40","author":"Ward","year":"2014","journal-title":"Rheum Dis Clin North Am"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1053\/j.ajkd.2010.08.036","article-title":"Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial","volume":"57","author":"Chen","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2014-206456","article-title":"Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up","volume":"75","author":"Mok","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"key":"R33-20230828","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s11255-015-1201-z","article-title":"The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis","volume":"48","author":"Zhang","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1093\/ndt\/gfp336","article-title":"Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids","volume":"24","author":"Pepper","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.22505","article-title":"Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis","volume":"56","author":"Gunnarsson","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R36-20230828","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/art.27541","article-title":"Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"(6 Suppl 2)","key":"R37-20230828","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.reuma.2010.06.002","article-title":"[Use of rituximab in the treatment of lupus patients. The LESIMAB database]","author":"Marenco","year":"2010","journal-title":"Reumatol Clin"},{"key":"R38-20230828","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2215\/CJN.04030808","article-title":"Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome","volume":"4","author":"Melander","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R39-20230828","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/ar1954","article-title":"Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study","volume":"8","author":"Vigna-Perez","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R40-20230828","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R41-20230828","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/ket462","article-title":"Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study","volume":"53","author":"Moroni","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"R43-20230828","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R44-20230828","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0961203312465781","article-title":"Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE","volume":"22","author":"Dooley","year":"2013","journal-title":"Lupus"},{"key":"R45-20230828","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"key":"R46-20230828","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38790","article-title":"Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study","volume":"66","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R47-20230828","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R48-20230828","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"key":"R49-20230828","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1186\/ar3738","article-title":"Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial","volume":"14","author":"Ginzler","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"R50-20230828","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jbspin.2009.03.010","article-title":"Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects","volume":"76","author":"Renaudineau","year":"2009","journal-title":"Joint Bone Spine"},{"key":"R51-20230828","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R52-20230828","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nrrheum.2013.136","article-title":"Future prospects in biologic therapy for systemic lupus erythematosus","volume":"9","author":"Stohl","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"R53-20230828","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13075-015-0741-z","article-title":"Treatment of systemic lupus erythematosus patients with the BAFF antagonist \u2018peptibody\u2019 blisibimod (AMG 623\/A-623): results from randomized, double-blind phase 1a and phase 1b trials","volume":"17","author":"Stohl","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R54-20230828","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2174\/092986730607220401123549","article-title":"Mizoribine and mycophenolate mofetil","volume":"6","author":"Ishikawa","year":"1999","journal-title":"Curr Med Chem"},{"key":"R55-20230828","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.3760\/cma.j.issn.0366-6999.20140627","article-title":"Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis","volume":"127","author":"Feng","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"R56-20230828","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/19420862.2015.1007810","article-title":"Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-alpha receptor 1 antibody","volume":"7","author":"Peng","year":"2015","journal-title":"MAbs"},{"key":"R57-20230828","first-page":"719","article-title":"Target modulation of a type i interferon (IFN) gene signature with sifalimumab or anifrolumab in systemic lupus erythematosus (SLE) patients in two open label phase 2 Japanese trials","volume":"66","author":"Morehouse","year":"2014","journal-title":"Arthritis Rheum"},{"issue":"(suppl 3)","key":"R58-20230828","doi-asserted-by":"crossref","first-page":"A164","DOI":"10.1136\/annrheumdis-2013-eular.528","article-title":"LB0003 a randomized controlled study of laquinimod in active lupus nephritis patients in combination with standard of care","volume":"72","author":"Jayne","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R59-20230828","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/0002-9343(83)90338-8","article-title":"Prognostic factors in lupus nephritis. Contribution of renal histologic data","volume":"75","author":"Austin","year":"1983","journal-title":"Am J Med"},{"key":"R60-20230828","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/acr.20441","article-title":"Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring","volume":"63","author":"Hsieh","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R61-20230828","first-page":"779","article-title":"The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature","volume":"72","author":"Esdaile","year":"1989","journal-title":"Q J Med"},{"key":"R62-20230828","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000184012","article-title":"Tubulointerstitial disease in lupus nephritis: relationship to immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis","volume":"44","author":"Park","year":"1986","journal-title":"Nephron"},{"key":"R63-20230828","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1046\/j.1523-1755.2000.00272.x","article-title":"A new morphologic index for the evaluation of renal biopsies in lupus nephritis","volume":"58","author":"Hill","year":"2000","journal-title":"Kidney Int"},{"key":"R64-20230828","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0046-8177(82)80268-2","article-title":"Pathologic changes in the renal tubule in systemic lupus erythematosus","volume":"13","author":"Schwartz","year":"1982","journal-title":"Hum Pathol"},{"key":"R65-20230828","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0344-0338(11)80252-9","article-title":"The long-term prognosis of the primary glomerulonephritides. A morphological and clinical analysis of 1747 cases","volume":"188","author":"Bohle","year":"1992","journal-title":"Pathol Res Pract"},{"key":"R66-20230828","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.4049\/jimmunol.1001983","article-title":"In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis","volume":"186","author":"Chang","year":"2011","journal-title":"J Immunol"},{"key":"R67-20230828","doi-asserted-by":"crossref","first-page":"271694","DOI":"10.1155\/2011\/271694","article-title":"Murine models of systemic lupus erythematosus","volume":"2011","author":"Perry","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"R68-20230828","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ki.2008.191","article-title":"Analysis and classification of B-cell infiltrates in lupus and ANCA-associated vasculitis","volume":"74","author":"Steinmetz","year":"2008","journal-title":"Kidney Int"},{"key":"R69-20230828","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1177\/0961203311416533","article-title":"Discrepancies in glomerular and tubulointerstitial\/vascular immune complex IgG subclasses in lupus nephritis","volume":"20","author":"Satoskar","year":"2011","journal-title":"Lupus"},{"key":"R70-20230828","doi-asserted-by":"crossref","first-page":"230ra46","DOI":"10.1126\/scitranslmed.3008146","article-title":"Cell distance mapping identifies functional T follicular helper cells in inflamed human renal tissue","volume":"6","author":"Liarski","year":"2014","journal-title":"Sci Transl Med"},{"key":"R71-20230828","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1002\/art.38888","article-title":"Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis","volume":"66","author":"Kinloch","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R72-20230828","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/00007890-200104150-00011","article-title":"Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation","volume":"71","author":"Jurcevic","year":"2001","journal-title":"Transplantation"},{"key":"R73-20230828","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.healun.2010.05.025","article-title":"Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy","volume":"29","author":"Nath","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"R74-20230828","first-page":"3269","article-title":"Antivimentin antibody detection in recipients of heart-beating and nonheart beating donor kidneys","volume":"8","author":"Carter","year":"2005","journal-title":"Transplant Proc"},{"key":"R75-20230828","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2353\/ajpath.2007.060728","article-title":"Autoantibodies to vimentin cause accelerated rejection of cardiac allografts","volume":"170","author":"Mahesh","year":"2007","journal-title":"Am J Pathol"},{"key":"R76-20230828","doi-asserted-by":"crossref","first-page":"106904","DOI":"10.1155\/2015\/106904","article-title":"The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy","volume":"2015","author":"Moroni","year":"2015","journal-title":"J Immunol Res"},{"key":"R78-20230828","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.ki.5002187","article-title":"Quantification of dendritic cell subsets in human renal tissue under normal and pathological conditions","volume":"71","author":"Woltman","year":"2007","journal-title":"Kidney Int"},{"key":"R79-20230828","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1681\/ASN.2011070680","article-title":"The renal mononuclear phagocytic system","volume":"23","author":"Nelson","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R80-20230828","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/j.1523-1755.2005.00502.x","article-title":"Antigen presentation by dendritic cells in renal lymph nodes is linked to systemic and local injury to the kidney","volume":"68","author":"Dong","year":"2005","journal-title":"Kidney Int"},{"key":"R81-20230828","doi-asserted-by":"crossref","first-page":"706","DOI":"10.4049\/jimmunol.180.2.706","article-title":"The kidney-renal lymph node-system contributes to cross-tolerance against innocuous circulating antigen","volume":"180","author":"Lukacs-Kornek","year":"2008","journal-title":"J Immunol"},{"key":"R82-20230828","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/01.TP.0000122183.60680.C9","article-title":"In vivo-mobilized kidney dendritic cells are functionally immature, subvert alloreactive T-cell responses, and prolong organ allograft survival","volume":"77","author":"Coates","year":"2004","journal-title":"Transplantation"},{"key":"R83-20230828","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2007060684","article-title":"Renal dendritic cells stimulate IL-10 production and attenuate nephrotoxic nephritis","volume":"19","author":"Scholz","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R84-20230828","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/ki.2008.394","article-title":"Dendritic cells facilitate accumulation of IL-17 T cells in the kidney following acute renal obstruction","volume":"74","author":"Dong","year":"2008","journal-title":"Kidney Int"},{"key":"R85-20230828","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/sj.ki.5002132","article-title":"Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury","volume":"71","author":"Dong","year":"2007","journal-title":"Kidney Int"},{"key":"R86-20230828","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1681\/ASN.2010101072","article-title":"Kideny dendritic cells induce innate immunity against bacterial pyelonephritis","volume":"22","author":"Tittel","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R87-20230828","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1681\/ASN.2009060592","article-title":"IL-10\/TGF-beta-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis","volume":"21","author":"Cao","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R88-20230828","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1681\/ASN.2009060615","article-title":"Distinct macrophage phenotypes contribute to kidney injury and repair","volume":"22","author":"Lee","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R89-20230828","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.4049\/jimmunol.1003010","article-title":"A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis","volume":"186","author":"Bethunaickan","year":"2011","journal-title":"J Immunol"},{"key":"R90-20230828","doi-asserted-by":"crossref","first-page":"988","DOI":"10.4049\/jimmunol.1103031","article-title":"Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis","volume":"189","author":"Berthier","year":"2012","journal-title":"J Immunol"},{"key":"R91-20230828","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.molimm.2007.04.029","article-title":"Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis","volume":"45","author":"Fiore","year":"2008","journal-title":"Mol Immunol"},{"key":"R92-20230828","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/ki.2011.32","article-title":"The possible role of ChemR23\/Chemerin axis in the recruitment of dendritic cells in lupus nephritis","volume":"79","author":"De Palma","year":"2011","journal-title":"Kidney Int"},{"key":"R93-20230828","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest"},{"key":"R94-20230828","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni.3326","article-title":"Self-reactive IgE exacerbates interferon responses associated with autoimmunity","volume":"17","author":"Henault","year":"2016","journal-title":"Nat Immunol"},{"key":"R95-20230828","first-page":"94","article-title":"Serum IgE concentrations, disease activity, and atopic disorders in systemic lupus erythematosus","volume":"50","author":"Elkayam","year":"1995","journal-title":"Allergy"},{"key":"R96-20230828","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/ard.57.11.660","article-title":"IgE and non-IgE mediated allergic disorders in systemic lupus erythematosus","volume":"57","author":"Morton","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"R97-20230828","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/0962935031000097709","article-title":"Allergic diseases, drug adverse reactions and total immunoglobulin E levels in lupus erythematosus patients","volume":"12","author":"Wozniacka","year":"2003","journal-title":"Mediators Inflamm"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201609000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T22:33:20Z","timestamp":1748990000000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201609000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000319","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}